Trials / Completed
CompletedNCT05606913
A Study of IBI362 in Participants With Type 2 Diabetes
Efficacy and Safety of IBI362 Versus Dulaglutide as add-on to Metformin and/or SGLT2 Inhibitor or TZD in Subjects With Type 2 Diabetes (DREAMS-2)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 731 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in China. The aim of the trial is to evaluate efficacy and Safety of IBI362 Versus dulaglutide as add-on to Metformin and/or SGLT2 inhibitor or TZD in Subjects With Type 2 Diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dulaglutide | Dulaglutide administered subcutaneously (SC) once a week. |
| DRUG | IBI362 | IBI362 administered subcutaneously (SC) once a week. |
Timeline
- Start date
- 2023-01-06
- Primary completion
- 2024-01-26
- Completion
- 2024-04-09
- First posted
- 2022-11-07
- Last updated
- 2024-08-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05606913. Inclusion in this directory is not an endorsement.